The next 6 -8 weeks appear to be the crescendo of the MSB Journey! COVID-19 trial, CHF and back pain readouts. I feel that the risk is somewhat mitigated due to Grunenthal partnership for back pain. The previously published data on Revascor CHF and last but not least the 12 patient study and the confidence of SI in various interviews as well as the cap raising for increased manufacturing prior to outcome of 300 patient trial.
IF the results of all 3 are relatively positive the SP should be close to $20. Not long to wait to find out the outcome!!!
GLTAH
The next 6 -8 weeks appear to be the crescendo of the MSB...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.18 |
Change
-0.005(0.42%) |
Mkt cap ! $1.341B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.20 | $1.14 | $10.44M | 8.934M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 45750 | $1.17 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.18 | 1476 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.18 |
Change
-0.005 ( 0.31 %) |
||||
| Open | High | Low | Volume | ||
| $1.18 | $1.20 | $1.14 | 1465927 | ||
| Last updated 15.59pm 24/05/2024 ? | |||||
| MSB (ASX) Chart |